Radiation- versus surgery-based treatment for patients with resectable IIIC1 cervical adenocarcinoma

· 2026-01-08

To describe the utilization trend of radiation-based and surgery-based treatment in patients with resectable IIIC1 cervical adenocarcinoma and explore the optimal treatment strategy for these patients. Patients with resectable IIIC1 cervical adenocarcinoma in 2005-2022 from Surveillance, Epidemiology, and End Results program (SEER) were analyzed. Trends over time in the utilization of radiation- and surgery-based treatment were plotted and estimated using Mantel-Haenszel test. Logistic regression analysis was performed to identify factors associated with the utilization of treatment. Survival outcomes were assessed and compared using Kaplan-Meire method and log-rank test, respectively. Inverse probability of treatment weighting (IPTW) was performed for adjustment of baseline characteristics. Sensitivity analysis was conducted using a cohort of cervical adenocarcinoma patients from our institution. The utilization of radiation-based treatment has grown steadily from 2005 to 2022 while the trend for surgery-based treatment showed opposite way (P = 0.002). Age, year of diagnosed, tumor size and T stage impacted the utilization of radiation-based treatment (All P < 0.05). Surgery-based treatment demonstrated superior overall survival (HR = 0.55, 95%CI:0.44-0.69; P < 0.001) and cancer specific survival (HR = 0.58, 95%CI:0.45-0.75; P < 0.001) to radiation-based treatment before adjustment of IPTW. However, no significant differences were observed in overall survival (HR = 0.77, 95%CI:0.56-1.05; P = 0.1) and cancer specific survival (HR = 0.86, 95%CI:0.60-1.23; P = 0.4) after baseline characteristics were balanced. Besides, the cohort from our institution further verified that similar survival outcomes were observed between two treatment strategies. The utilization of radiation-based treatment has increased over time and showed non-inferior efficacy for patients with resectable IIIC1 cervical adenocarcinoma when compared to surgery-based treatment.
Funding

Innovation Fund

2023-I2M-C

Innovation Fund

T-B-039

National Key Research and Development Program of China

Ministry of Science and Technology of the People's Republic of China

2022YFC2407100

Ministry of Science and Technology of the People's Republic of China

2022YFC2407101